These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 7143200)

  • 1. [Conditions for applying enteric coatings based on Eudragit L 30 D].
    Dechesne JP; Delporte JP; Jaminet F; Venturas K
    J Pharm Belg; 1982; 37(4):273-82. PubMed ID: 7143200
    [No Abstract]   [Full Text] [Related]  

  • 2. Retard implantation tablets on a matrix base with Eudragit as a structural substance.
    Korsatko W
    Pharmazie; 1982 Apr; 37(4):272-3. PubMed ID: 7100251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colonic release and reduced intestinal tissue damage of coated tablets containing naproxen inclusion complex.
    Piao ZZ; Lee MK; Lee BJ
    Int J Pharm; 2008 Feb; 350(1-2):205-11. PubMed ID: 17928177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of polymeric subcoats on the drug release properties of tablets powder-coated with pre-plasticized Eudragit L 100-55.
    Sauer D; Watts AB; Coots LB; Zheng WC; McGinity JW
    Int J Pharm; 2009 Feb; 367(1-2):20-8. PubMed ID: 18848872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
    Sauer D; Zheng W; Coots LB; McGinity JW
    Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of time-dependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets.
    Akhgari A; Sadeghi F; Garekani HA
    Int J Pharm; 2006 Aug; 320(1-2):137-42. PubMed ID: 16782290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery.
    Ibekwe VC; Fadda HM; Parsons GE; Basit AW
    Int J Pharm; 2006 Feb; 308(1-2):52-60. PubMed ID: 16356670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between drug dissolution and leaching of plasticizer for pellets coated with an aqueous Eudragit S100:L100 dispersion.
    Bando H; McGinity JW
    Int J Pharm; 2006 Oct; 323(1-2):11-7. PubMed ID: 16815652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative method for enteric coating of HPMC capsules resulting in ready-to-use enteric-coated capsules.
    Huyghebaert N; Vermeire A; Remon JP
    Eur J Pharm Sci; 2004 Apr; 21(5):617-23. PubMed ID: 15066662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with Eudragit-S coated mesalamine (Asacol) in inflammatory bowel disease: adverse events.
    Nichols TW
    J Clin Gastroenterol; 1994 Mar; 18(2):181. PubMed ID: 8189029
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative and experimental pathology of fibrosing colonopathy.
    van Velzen D; Ball LM; Dezfulian AR; Southgate A; Howard CV
    Postgrad Med J; 1996 Mar; 72 Suppl 2():S39-48; discussion S49-51. PubMed ID: 8869182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal growth formation in melt extrudates.
    Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel concept in enteric coating: a double-coating system providing rapid drug release in the proximal small intestine.
    Liu F; Lizio R; Meier C; Petereit HU; Blakey P; Basit AW
    J Control Release; 2009 Jan; 133(2):119-24. PubMed ID: 18930772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of Eudragit type on the dissolution rate of acetylsalicylic acid from matrix tablets.
    Jovanović M; Jovicić G; Djurić Z; Agbaba D; Karljiković-Rajić K; Nikolić L; Radovanović J
    Acta Pharm Hung; 1997 Nov; 67(6):229-34. PubMed ID: 9423294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of hydroxyethylcellulose on the drug release properties of theophylline pellets coated with Eudragit RS 30 D.
    Zheng W; Sauer D; McGinity JW
    Eur J Pharm Biopharm; 2005 Jan; 59(1):147-54. PubMed ID: 15567312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ionic strength dependence of dissolution for Eudragit S-100 coated pellets.
    Kararli TT; Kirchhoff CF; Truelove JE
    Pharm Res; 1995 Nov; 12(11):1813-6. PubMed ID: 8592693
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of an enteric-coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis.
    Huyghebaert N; Vermeire A; Rottiers P; Remaut E; Remon JP
    Eur J Pharm Biopharm; 2005 Oct; 61(3):134-41. PubMed ID: 15967652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eudragit FS 30 D: a new pH-sensitive polymer covering for mesalamine.
    Potestà P
    Eur Rev Med Pharmacol Sci; 2001; 5(1):30. PubMed ID: 11860220
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative evaluation of interpolyelectrolyte complexes of chitosan with Eudragit L100 and Eudragit L100-55 as potential carriers for oral controlled drug delivery.
    Moustafine RI; Margulis EB; Sibgatullina LF; Kemenova VA; Van den Mooter G
    Eur J Pharm Biopharm; 2008 Sep; 70(1):215-25. PubMed ID: 18691856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets.
    Zaghloul AA; Faltinek J; Vaithiyalingam SR; Reddy IK; Khan MA
    Pharmazie; 2001 Apr; 56(4):321-4. PubMed ID: 11338673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.